EsoCap completes patient recruitment in ACESO Phase II trial in eosinophilic esophagitis
05 sept. 2023 03h30 HE
|
EsoCap AG
EsoCap's novel targeted delivery platform is designed to increase mucosal contact time and drug deposition in the esophagus ESO-101, EsoCap's lead product candidate, consists of a capsule with a...
Global Barrett’s Esophagus Market Size To Grow USD 12.5 Billion By 2032 | CAGR of 6.4%
29 mai 2023 14h00 HE
|
SPHERICAL INSIGHTS LLP
New York, United States , May 29, 2023 (GLOBE NEWSWIRE) -- The Global Barrett’s Esophagus Market Size is to grow from USD 6.7 billion in 2022 to USD 12.5 billion by 2032, at a Compound Annual Growth...
EsoCap holds a multidisciplinary advisory board meeting on Barrett’s esophagus
14 juin 2022 03h32 HE
|
EsoCap AG
EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in ZurichEsoCap’s technology for the topical treatment of...
Stella Diagnostics CEO Discusses Competitive Advantage in Early Cancer Detection During Audio Interview with SmallCapVoice.com
15 févr. 2022 08h00 HE
|
Stella Diagnostics, Inc. and SmallCapVoice.com
AUSTIN, Texas, Feb. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Joe Abdo, CEO of Stella Diagnostics Inc. (OTC Pink: SLDX) (“the...
EsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagus
10 janv. 2022 05h32 HE
|
EsoCap AG
Licensing deal grants EsoCap exclusive access to Upadia’s monoclonal antibodies for a local therapy for Barrett’s esophagusBarrett’s esophagus, a disease of the esophagus with high unmet medical need,...
PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™
24 juin 2019 10h46 HE
|
PAVmed Inc.
NEW YORK, June 24, 2019 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product medical device company, today announced that its...
PAVmed Subsidiary Lucid Diagnostics Files 510(k) Submission with FDA for EsoCheck™ Cell Collection Device
29 nov. 2018 07h30 HE
|
PAVmed Inc.
NEW YORK, Nov. 29, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today announced that the...
PAVmed Provides Business Update
17 oct. 2018 07h30 HE
|
PAVmed Inc.
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical device company, today provided an update on...
Interpace Diagnostics CEO Provides Corporate Update
10 oct. 2018 08h30 HE
|
Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group (NASDAQ: IDXG) is pleased to provide a corporate update to shareholders on current business activities from its Chief...